Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically the use of RU58841 by individuals who did not respond to dutasteride. Users share experiences with maintaining hair using RU58841 and mention trying pyrilutamide and the upcoming availability of pp405.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The user switched to dutasteride and saw palmetto, along with a topical mix of minoxidil and finasteride, due to continued hair shedding. They hope for improvement despite concerns about saw palmetto's effectiveness.

The conversation is about choosing an additional topical treatment for hair loss, with options being fluridil, topical spiro, or alfatradiol, alongside existing treatments like dutasteride, oral minoxidil, latanoprost, and RU58841. Opinions vary on the effectiveness of adding these topicals, with some suggesting RU58841 is sufficient.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.

The user has been using dutasteride for 8 months, oral minoxidil for 3 years, and topical minoxidil on temples, with recent microneedling. They experienced thinning after switching from finasteride to dutasteride and are hoping for improvement by the 12-month mark.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The user has been using finasteride and minoxidil for 7 months, seeing thicker hair but no temple regrowth, and is considering switching to dutasteride. Another person suggested trying microneedling on the temples before changing medications.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

A 23-year-old shares progress in hair quality after 4 months using dutasteride, topical minoxidil, and other treatments, noting improved crown thickness but persistent temple thinning. They switched from finasteride to dutasteride due to side effects and started testosterone replacement therapy, which they believe helps mitigate side effects.

A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.

The conversation is about finding providers for Dutasteride Mesotherapy in the US, which is more common in Europe. The user is asking if any mesotherapy/PRP clinic could offer it if they provide the Dutasteride.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Travoprost may be more effective than minoxidil for hair growth and can be used alongside it, but its effectiveness is debated due to inconsistent dosing results. Travoprost is expensive and not widely used, with alternatives like latanoprost and bimatoprost being more accessible.

A Spanish doctor shared a video about Verteporfin for hair loss. The conversation mentions Minoxidil, finasteride, and RU58841 as treatments.

The user has been using Multi-Peptide and Biotin serums for hair loss and is considering starting Fin and Minoxidil. They are seeking feedback on any visible improvement between May and June.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user has been experiencing hair loss for over 5 years and is currently using a topical treatment of finasteride, minoxidil, and tretinoin, along with derma rolling and a hair growth oil. They have previously tried oral finasteride, pyrithione zinc, RU58841, and dutasteride, but are seeking advice on whether to retry dutasteride or find a more reliable source for RU58841 due to ongoing hair density loss.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user is experiencing hair loss and has been using RU58841 but is considering pyrilutamide and minoxidil, avoiding finasteride due to side effects. Another user suggests finasteride or dutasteride as essential, possibly in topical form, while dismissing saw palmetto as ineffective.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

A 28-year-old man with hair loss is seeing regrowth in his temple area after 2 months of treatment with Dutasteride, a 1.5mm Dermaroller, topical Minoxidil, and Biotin supplements. He also notes an unexpected positive side effect of Dutasteride clearing up his light facial acne.

User experienced severe brain fog and anxiety from oral dutasteride and is considering dutasteride injections with PRP for hair loss, while currently using finasteride and oral minoxidil. They seek others' experiences with dutasteride mesotherapy and its side effects.